#高警訊藥品

Palliative treatment of advanced prostate cancer.

Antineoplastic Agent, Gonadotropin-Releasing Hormone Agonist
Leuprorelin acetate is a synthetic nonapeptide agonist of naturally occurring gonadotropin releasing hormone (GnRH) that, when given continuously, inhibits pituitary gonadotropin secretion and suppresses testicular steroidogenesis inmales.

Onset of action:
1. Following transient increase, testosterone suppression occurs in ~2 to 4 weeks of continued therapy.
2. Onset of therapeutic suppression for precocious puberty: (Leuprolide) 2 to 4 weeks; (Leuprolide depot) 1 month
Distribution:
1. Vd: 27 L
2. Protein binding: 43% to 49%
Metabolism:
1. Metabolized to smaller inactive peptides, then may be further catabolized; Major metabolite, pentapeptide (M-1)
2. Half-life elimination: ~3 hours
Excretion:
1. Urine (<5% as parent and major metabolite)
2. Clearance: 8.34 L/hour

1. Hypersensitivity to leuprolide, GnRH, GnRH-agonist analogs, or any component of the formulation
2. Pregnancy
3. Undiagnosed abnormal vaginal bleeding

X; Use is contraindicated during pregnancy

Use is contraindicated in nursing women

Hot flashes, malaise, nausea and fatigue, transient local irritation at the site of injection

ELIGARD 22.5 mg is administered as a single subcutaneous injection every 3 months.

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).